文章：

经典霍奇金淋巴瘤治疗的最新进展：新疗法时代

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

原文发布日期：2021-07-09

DOI: 10.1038/s41408-021-00518-z

类型: Review Article

开放获取: 是

英文摘要：

Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.
 

摘要翻译： 

霍奇金淋巴瘤是一种高度可治愈的疾病。尽管大多数患者在一线治疗后达到完全缓解，但仍存在关键的未满足临床需求，包括复发/难治性疾病、治疗相关并发症、生活质量受损以及60岁以上患者预后较差。将检查点抑制剂和抗体药物偶联物等新型疗法纳入一线治疗、采用序贯治疗策略以及进一步个体化调整治疗强度，可能有助于解决这些需求。本文概述了经典霍奇金淋巴瘤患者从一线治疗到异基因造血干细胞移植的当前治疗方案，并介绍了该领域的新兴临床试验。

原文链接：

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies